Diabetes Crisis in Europe: Urgent Public Health and Economic Challenge

By João L. Carapinha

November 12, 2024

A recently published article by Euractiv provides a comprehensive analysis of the escalating diabetes crisis in Europe, and highlights its significant public health implications, economic burdens, and societal challenges associated with this health issue.

Public Health Crisis

The article describes the rising prevalence of diabetes, particularly Type 2 diabetes, as a “tsunami” that threatens to overwhelm healthcare systems. This rise is driven by factors such as obesity, an ageing population, and poor dietary habits.

Economic Burden

The economic impact of diabetes on Europe is substantial. In 2021, diabetes-related expenditure in Europe totalled approximately €170 billion, which is more than the total EU funding committed to Ukraine since the Russian invasion. This expenditure accounts for 19.6% of global diabetes spending.

The average annual cost per person with diabetes in Europe was around €2,760. For example, Switzerland spent nearly €11,600 per person with diabetes, while the UK, France, and Germany spent between €5,200 and €6,000 per person annually.

Prevalence and Mortality

Spain and Portugal have the highest diabetes prevalence rates in Europe, with nearly 15% and 13% of adults diagnosed, respectively. Most other European countries report prevalence rates of around 8-9%.

Czechia had the highest diabetes-related mortality in 2021, with 43.4 deaths per 100,000 population. Mortality rates were notably higher among men than women across Europe.

Lifestyle Factors

The global prevalence of diabetes is projected to surge, reaching 12.2% of the population by 2045. Type 2 diabetes, which accounts for 95% of all diabetes cases, is heavily influenced by age, poor diet, and sedentary lifestyles. Over 30% of the population in many European countries exhibited insufficient physical activity, and soft drink consumption averaged 98 litres per capita in 2022.

Future Projections

The number of adults living with diabetes in Europe is projected to increase from 32 million today to 35 million by 2030. By 2045, it is estimated that 1 in 10 people in the region will have diabetes.

Policy and Interventions

The article emphasizes the need for immediate and coordinated action to mitigate the impact of diabetes. Policies such as the introduction of a sugar-sweetened drinks tax, food reformulation to reduce calories, fat, salt, and sugar content are on the cards. Regulating the marketing of unhealthy food to children are also being considered or implemented in various European countries.

Broader Implications

The economic burden of the diabetes crisis in Europe includes direct medical expenses such as hospitalizations, medications, and outpatient care. It also includes indirect costs – lost productivity and premature mortality. These costs are limiting European economic growth. Thus, the need for a bold vision to address this crisis as Europe works towards creating a true Health Union.

In summary, Europe is confronted with a diabetes crisis, with severe public health and economic consequences. There’s an urgent need for comprehensive policy interventions to tackle this growing health challenge effectively.

Reference url

Recent Posts

semaglutide NAION risk
    

Semaglutide NAION Risk: EMA Review Initiated Amid Conflicting Evidence

🔍 Is semaglutide linked to vision loss?

The European Medicines Agency’s PRAC is currently reviewing the potential risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with semaglutide-containing medicines, including popular treatments like Ozempic and Wegovy. With recent studies yielding conflicting evidence, this review is crucial for patient safety and the future of these therapies.

Read the full article to understand the implications and what this could mean for healthcare providers and patients alike!

#SyenzaNews #Pharmaceuticals #HealthcarePolicy

cervical cancer screening
        

Cost-Effective Cervical Cancer Screening Strategies for Women with HIV in KwaZulu-Natal

💡 *Are single-visit cervical cancer screenings the key to better health outcomes in high HIV prevalence areas?*
A recent study from KwaZulu-Natal, South Africa reveals that repeat single-visit cervical cancer screening using HPV DNA testing is not only the most effective but also the most cost-effective approach for women living with HIV. This aligns with WHO recommendations for comprehensive cervical cancer elimination strategies.

Explore the insights and implications of this vital research that could transform cervical cancer prevention in resource-limited settings.

#SyenzaNews #HealthEconomics #oncology #GlobalHealth

EU Health Technology Assessment
          

Advancing EU Health Technology Assessment: Insights from the HAG Meeting

💡 How can the EU Health Technology Assessment reshape healthcare delivery?

The recent meeting of the Heads of HTA Agencies Group heralds a new era with the operationalization of the EU’s Health Technology Assessment Regulation, aiming to streamline processes and enhance collaboration across member states.

This initiative promises to improve data transparency, foster innovative health technologies, and ultimately, drive better patient outcomes.

Curious to learn more about these significant updates and what they mean for the future of health assessments in the EU? Jump into the full article!

#SyenzaNews #HealthTech #HealthEconomics #DigitalTransformation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.